TargetTransitional endoplasmic reticulum ATPase(Homo sapiens (Human))
University Of Pittsburgh
Curated by ChEMBL
University Of Pittsburgh
Curated by ChEMBL
Affinity DataKi: 740nMAssay Description:Uncompetitive inhibition of recombinant human full length Avi-tagged p97 (1 to 806 residues) expressed in Escherichia coli Rosetta 2(DE3) using 20 uM...More data for this Ligand-Target Pair
TargetTransitional endoplasmic reticulum ATPase(Homo sapiens (Human))
University Of Pittsburgh
Curated by ChEMBL
University Of Pittsburgh
Curated by ChEMBL
Affinity DataKi: 3.50E+3nMAssay Description:Competitive inhibition of recombinant human full length Avi-tagged p97 (1 to 806 residues) expressed in Escherichia coli Rosetta 2(DE3) using 20 uM A...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 0.5nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of Trypanosoma cruzi recombinant cruzain using Z-FR-AMC as substrate after 5 mins by fluorescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant JNK1 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 10(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant JNK3 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK2(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-tagged Plk2 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of Trypanosoma cruzi recombinant cruzain using Z-FR-AMC as substrate after 5 mins by fluorescence assayMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 10(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of recombinant JNK3 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: <6nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK2(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of GST-tagged Plk2 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 10(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of recombinant JNK3 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant JNK2 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 8nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK2(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of GST-tagged Plk2 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measu...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK1(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of GST-tagged Plk1 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant JNK2 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK2(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of GST-tagged Plk2 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant JNK1 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK2(Homo sapiens (Human))
Elan Pharmaceuticals
Curated by ChEMBL
Elan Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of GST-tagged Plk2 (unknown origin) assessed as inhibition of DEKTDDED phosphorylation at Thr1342 after 60 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 10nMAssay Description:Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphory...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Imago Pharmaceuticals
US Patent
Imago Pharmaceuticals
US Patent
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Compounds as described herein (compounds of Formula I, e.g., compounds of the above Examples) are tested for their in vitro kinase activities using v...More data for this Ligand-Target Pair